<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222376</url>
  </required_header>
  <id_info>
    <org_study_id>DIA-1031-13/14-1</org_study_id>
    <nct_id>NCT02222376</nct_id>
  </id_info>
  <brief_title>Effect of Topic Pirfenidone in Diabetic Ulcers</brief_title>
  <acronym>PirDFI</acronym>
  <official_title>Effect of Treatment of Diabetic Foot Ulcers With Topic 8% 1-phenyl-5-methyl-2-[1h]-Pyridone (Pirfenidone) Combined With Modified Disulfur Diallyl Oxide (Odd-m) in Gel.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pirfenidone is a synthetic molecule, which acts as a potent modulator of the effect of
      various cytokines (TNF-α, transforming growth factor-β, platelet derived growth factor and
      vascular endothelial growth factor, among others) that possesses anti-inflammatory and
      anti-fibrinolytic properties.

      The aim of this study is to compare the effect of topic treatment with pirfenidone compared
      to conventional treatment in chronic diabetic foot ulcers.

      The hypothesis is that treatment with topic pirfenidone in chronic diabetic foot ulcers
      (Wagner 1 to 2) reduces the ulcer size and shortens the healing time compared to conventional
      treatment. This is a randomized, controlled and crossover study. Patients will be randomly
      assigned to conventional treatment or topic pirfenidone for eight weeks. At the end of this
      period they will change groups. Each week ulcers will be for size, depth, length and evidence
      of infection. The ulcers will have proper debridement in the conventional treatment group and
      debridement plus topical pirfenidone application in the pirfenidone group. Subjects will be
      instructed to do daily ulcer cleansing and for those in the topical pirfenidone group, in
      addition to cleansing they will be instructed to apply the gel twice a day.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ulcer size</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Healed ulcers</measure>
    <time_frame>16 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse effects</measure>
    <time_frame>16 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Healing time</measure>
    <time_frame>16 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly ulcer debridement and daily cleansing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly ulcer debridement, daily cleansing, plus twice a day topical pirfenidone application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Twice a day topical application</description>
    <arm_group_label>Pirfenidone</arm_group_label>
    <other_name>Kitoscell Q</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Debridement</intervention_name>
    <description>Weekly ulcer debridement</description>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_label>Pirfenidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women

          2. Type 1 or 2 diabetes

          3. Age ≥ 18 years

          4. Wagner 1 or 2 diabetic foot ulcer

          5. Diabetic ulcer for more than 8 weeks duration

          6. Willing to participate in the study with signed informed consent

        Exclusion Criteria:

          1. Ankle/brachial index &lt; 0.4 (critic ischemia)

          2. Use topical or systemic antibiotics

          3. Inability to attend to the weekly evaluations

          4. Inability to do daily ulcer cleansing

          5. Autoimmune diseases

          6. Active pharmacologic topical or systemic ulcer treatment

          7. Treatment with immunosuppressors such as steroids, radiotherapy, chemotherapy

          8. Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco J Gomez-Perez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2014</study_first_submitted>
  <study_first_submitted_qc>August 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic ulcer, diabetic foot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

